Kyung In Woo1, J William Harbour. 1. Ocular Oncology Service, Department of Ophthalmology & Visual Sciences,Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA.
Abstract
OBJECTIVE: To obtain a more accurate understanding of second primary tumors (SPTs) by analyzing a large number of SPTs from the published literature. METHODS: A literature search was performed to identify published cases of SPTs in patients with retinoblastoma. Patient age, radiation field, tumor location, and tumor type were analyzed for statistical association. RESULTS: The study included 676 SPTs in 602 patients. Median age at diagnosis of SPT was 13.0 years (range, 0.3-60.4 years) for all SPTs, 2.7 years for midline intracranial primitive neuroectodermal tumors, 13.0 years for sarcomas, 27.0 years for melanomas, and 29.0 years for carcinomas. The median age at which SPTs occurred inside the radiation field was younger than that for SPTs occurring outside the radiation field or in patients who did not undergo irradiation (P < .001). Sarcomas occurred more commonly inside the radiation field (P < .001). Melanomas, lipomas, leukemias, and lymphomas occurred more commonly outside the radiation field or in patients who did not undergo irradiation (P < .001). CONCLUSIONS: Retinoblastoma patients pass through multiple windows of susceptibility to specific SPTs. This information will aid health care providers in monitoring this high-risk group, and it provides new insights for studying the underlying genetic predisposition to SPTs.
OBJECTIVE: To obtain a more accurate understanding of second primary tumors (SPTs) by analyzing a large number of SPTs from the published literature. METHODS: A literature search was performed to identify published cases of SPTs in patients with retinoblastoma. Patient age, radiation field, tumor location, and tumor type were analyzed for statistical association. RESULTS: The study included 676 SPTs in 602 patients. Median age at diagnosis of SPT was 13.0 years (range, 0.3-60.4 years) for all SPTs, 2.7 years for midline intracranial primitive neuroectodermal tumors, 13.0 years for sarcomas, 27.0 years for melanomas, and 29.0 years for carcinomas. The median age at which SPTs occurred inside the radiation field was younger than that for SPTs occurring outside the radiation field or in patients who did not undergo irradiation (P < .001). Sarcomas occurred more commonly inside the radiation field (P < .001). Melanomas, lipomas, leukemias, and lymphomas occurred more commonly outside the radiation field or in patients who did not undergo irradiation (P < .001). CONCLUSIONS:Retinoblastomapatients pass through multiple windows of susceptibility to specific SPTs. This information will aid health care providers in monitoring this high-risk group, and it provides new insights for studying the underlying genetic predisposition to SPTs.
Authors: Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson Journal: Ophthalmology Date: 2020-05-15 Impact factor: 12.079
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Ibrahim Qaddoumi; Catherine A Billups; Michael Tagen; Clinton F Stewart; Jianrong Wu; Kathleen Helton; M Beth McCarville; Thomas E Merchant; Rachel Brennan; Tammy M Free; Vicki Given; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur Journal: Clin Cancer Res Date: 2017-07-01 Impact factor: 12.531
Authors: Linda J Szymanski; Maria E Sibug Saber; Jonathan W Kim; John L Go; Gabriel Zada; Narsing Rao; Kyle M Hurth Journal: Ocul Oncol Pathol Date: 2017-07-06